Figure 3

Functional analysis of CD4⁺and CD8⁺T-cells before and after treatment with Selectikine. (A) Frequencies (%) of proliferative CD4⁺ and CD8⁺ T-cells (Ki67⁺ HLA-DR⁺) on days 1 and 8 during the first and second treatment cycles. Dot plots represent HLA-DR versus Ki67 staining of CD8⁺ gated T-cells on days 1 and 8 during the first treatment cycle. The right dot plot shows expression of CCR7 and CD45RA of cells from gate (1), on day 8 of the first cycle. (B) Frequencies (%) of activated cells (CD38⁺ Bcl2^-) within CD4⁺ and CD8⁺ T-cells on days 1 and 8 during the first and second treatment cycle. Dot plots represent CD38 versus Bcl2 staining in CD8⁺ gated cells on days 1 and 8 during the first treatment cycle. The right dot plot represents CCR7 versus CD45RA repartition of activated CD8⁺ T-cells (1) on day 8 of the first cycle. (C) Absolute counts (cells/mm³) of effector memory (EM) CD8⁺ T-cells (CCR7^- CD45RA^-) on days 1 and 8 during the first and second treatment cycles. Graphs show individual values of 39 treated patients. Bars represent geometric mean values with 95% CI. (D) Frequency of GrB⁺ perforin⁺ cells in CD8⁺ gated cells on days 1 and 8 during the first and second treatment cycles. The box-and-whiskers graph shows geometric mean with 95% CI. (E) Expression of IFNγ and TNFα (%) in CD8⁺ T-cells on days 1 and 8 of the second cycle, after a 4-hour in vitro stimulation with PMA/ionomycin. Dot plot representation of IFNγ versus TNFα staining in CD8⁺ gated T-cells after in vitro stimulation. Box-and-whiskers graphs show geometric mean with 95% CI from 9 randomized patients treated with 0.075 to 0.9 mg/kg Selectikine alone. *P < 0.05, **P ≤ 0.01, ***P ≤ 0.005.